Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874881 | 1.00 | ENPP2 (0.42) | ENPP2PSMB5HDAC1HDAC6FAAH | |
| SCHEMBL12291363 | 0.99 | ENPP2 (0.41) | ENPP2PSMB5HDAC1HDAC6FAAH | |
| SCHEMBL6873844 | 0.94 | CHRNB2 (0.37) | ENPP2PSMB5HDAC1HDAC6 | |
| SCHEMBL10074455 | 0.92 | ENPP2 (0.39) | ENPP2PSMB5HDAC1HDAC6LPAR1 | |
| SCHEMBL10074987 | 0.92 | ENPP2 (0.39) | ENPP2PSMB5HDAC1HDAC6LPAR1 | |
| SCHEMBL13195308 | 0.92 | ENPP2 (0.43) | ENPP2PSMB5HDAC1HDAC6FAAH | |
| SCHEMBL13194661 | 0.92 | PSMB5 (0.39) | ENPP2PSMB5HDAC1HDAC6FAAH | |
| SCHEMBL10074154 | 0.91 | ENPP2 (0.38) | ENPP2PSMB5HDAC1HDAC6LPAR1 | |
| SCHEMBL13195333 | 0.91 | BACE1 (0.37) | PSMB5 | |
| SCHEMBL6872783 | 0.87 | CTSD (0.34) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2011026781-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2011-03-10 | — | — | WO | disclosed |
| EP-2292589-A1 | Novel multifunctional peptidase inhibitors, especially for medical use | IMTM GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258960-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | PEPD, CTSC, SERPINB1 | ENPP2 269/4885PSMB5 320/4885HDAC1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.